# Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor

> **NCT05745337** · PHASE1 · UNKNOWN · sponsor: **University of Vermont** · enrollment: 20 (estimated)

## Conditions studied

- Atrial Fibrillation
- Diastolic Dysfunction
- HFpEF - Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)

## Key facts

- **NCT ID:** NCT05745337
- **Lead sponsor:** University of Vermont
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-06
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05745337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05745337, "Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05745337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*